1. 2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer. (27th October 2022) Authors: Moore, Kathleen; Asch, Adam; Moreno, Victor; Calvo, Emiliano; Butler, Marcus; Zugazagoitia, Jon; Hong, David; Galal, Ahmed; Ostios, Lorena; de Miguel, Maria; Lin, Quan; Annareddy, Thejo; Brophy, Francine; Rosenberg, Marisa; Seiders, Theresa; Naidoo, Revashnee; Bath, Natalie; Saro, Jose; Norry, El... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Issue 8 (August 2022) Authors: Pagel, John M; Soumerai, Jacob D; Reddy, Nishitha; Jagadeesh, Deepa; Stathis, Anastasios; Asch, Adam; Salman, Huda; Kenkre, Vaishalee P; Iasonos, Alexia; Llorin-Sangalang, Judith; Li, Joanne; Zelenetz, Andrew D Journal: Lancet oncology Issue: Volume 23:Issue 8(2022) Page Start: 1021 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗